Vol. 5 No. 10 (2025)
Reimbursement Reviews

Semaglutide (Wegovy)

decorative image of the issue cover

Published October 17, 2025

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses Semaglutide injection (Wegovy); 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, or 2.4 mg; solution for subcutaneous injection in a prefilled pen.
  • Indication: As an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index of: 30 kg/m2 or greater (obesity), or 27 kg/m2 or greater (overweight) in the presence of at least 1 weight-related comorbidity such as hypertension, type 2 diabetes mellitus, dyslipidemia, or obstructive sleep apnea.